RxDoctor Payments Data

Robert Allison, MD

Internal Medicine · Dallas, TXNPI 1750339719

Payments from drug & device makers

$4,932in general payments, 2019–2025

Across 296 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$575
  • GSK$367
  • Amarin Pharma, Inc.$363
  • Astellas Pharma US Inc$363
  • Amgen$321
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,85198%
  • Education$812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,932 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$150,505
Medicare patients
324
Services billed
3,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$27,935
MounjaroTirzepatide18$23,864
JardianceEmpagliflozin14$23,205
XareltoRivaroxaban14$19,533
EliquisApixaban13$15,463
RybelsusSemaglutide12$11,710
JanuviaSitagliptin Phosphate15$11,017
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,704
LinzessLinaclotide11$5,555
Atorvastatin Calcium411$3,866
SynthroidLevothyroxine Sodium56$3,105
Icosapent Ethyl11$2,888
PaxlovidNirmatrelvir/Ritonavir26$2,858
Ezetimibe100$2,557
Amlodipine Besylate352$2,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,008$39,64633 claims
Boehringer IngelheimJardiance, Stiolto Respimat$111$29,90925 claims
Lilly USA, LLCMounjaro$77$23,86418 claims
Johnson & JohnsonXarelto$126$19,53314 claims
PfizerEliquis, Paxlovid$209$18,32239 claims
MerckJanuvia$287$11,01715 claims
AbbVieLinzess, Synthroid$233$8,66167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →